The management of subacute and chronic vascular aphasia: an updated review

Samwel Sylvester Msigwa, Xianglin Cheng
2020 The Egyptian Journal of Neurology Psychiatry and Neurosurgery  
Post-stroke aphasia (PSA) is an impairment of the generation or comprehension of language due to acute cerebrovascular lesions. Subacute phase span the 7th day to 24 weeks post-onset while > 6 months is termed chronic phase. Language recovery does not arise immediately in chronic PSA, unlike the acute phase. The majority of the treatment modalities in these two PSA phases are still in the infancy stage, facing dilemmas and considered experimental requiring constant updates. Hence, we aimed to
more » ... ence, we aimed to upgrade the existing literature regarding available PSA management options, advances, and drawbacks pertaining to subacute and chronic phases. Main text: In this review, we analyzed the management options for subacute and chronic vascular aphasia. MEDL INE, through PubMed, ScienceDirect, and Google Scholar were explored for English studies by utilizing the terms "stroke aphasia" Plus "vascular aphasia"; 160,753 articles were retrieved. The latest studies, published from 2016 to July 2020, were selected. Article headings and abstracts were analyzed for relevance and filtered; eventually, 92 articles were included in this review. Various management options were extracted as follows: noninvasive brain stimulation (NIBS), technology-based therapies, speech-language therapy (SLT), pharmacotherapy, music-based therapies, and psychosocial interventions. Conclusion: The PSA therapy evolves towards more intense SLT therapy, yet the optimal dosage of the emerging high-intensity therapies is controversial. As spinal and cerebellar NIBS, Telespeech, and E-mental health mark PSA's future, distinct pharmacological options remain a dilemma. Across the continuum of care, PSA-depression comorbidity and inadequate PSA post-discharge education to patient's families are the significant therapeutic challenges. Future therapeutic mechanisms, optimal dose/timing, and tolerability/safety exploration are obliged.
doi:10.1186/s41983-020-00224-w fatcat:vn3i2ovr7jfmjogpkolkvpoc3i